EDARBI® is the commercial brand name of Azilsartan Medoxomil Potassium Tablets, developed by Takeda Pharma A It is an oral angiotensin II type 1 receptor antagonist. It selectively blocks angiotensin II receptors on vascular smooth muscle to dilate blood vessels,…
Firazyr® is the commercial brand name of Icatibant Acetate Injection, developed by Takeda. It is a selective bradykinin B2 receptor antagonist. It competitively blocks bradykinin-mediated vasodilation and vascular permeability elevation, rapidly relieving acute edema attacks of hereditary angioedema. Main IndicationsOn-demand…
REBLOZYL® is the commercial brand name of Luspatercept for Injection, developed by Bristol Myers Squibb. It is a first-in-class erythroid maturation agent. It binds to transforming growth factor superfamily ligands to improve late-stage erythroid progenitor cell maturation, reduce ineffective erythropoiesis…
NESP® is the commercial brand name of Darbepoetin Alfa Injection, developed by Kyowa Kirin Co., Ltd. It is a long-acting recombinant human erythropoietin analogue. It binds to erythropoietin receptors on bone marrow erythroid progenitor cells to stimulate red blood cell…
MonoFer® is the commercial brand name of Iron Isomaltoside Injection, developed by Pharmacosmos. It is a stable high-molecular-weight intravenous iron complex. It releases bioavailable ferric iron inside macrophages to replenish systemic iron reserves and stimulate erythropoiesis, enabling single high-dose rapid…
Ferinject® is the commercial brand name of Ferric Carboxymaltose Injection, developed by Vifor (International) Inc. and manufactured by IDT Biologika GmbH. It is a stable intravenous iron preparation with high molecular weight complex structure. It delivers high-dose elemental iron via…
Mulpleta® is the commercial brand name of Lusutrombopag Tablets, developed by Shionogi Inc. It is an oral thrombopoietin receptor agonist. It selectively activates thrombopoietin receptors on bone marrow megakaryocytes to promote megakaryocyte proliferation and maturation, raising peripheral platelet counts and…
Ruilisheng® is the commercial brand name of Romiplostim N01 for Injection, developed by Qilu Pharmaceutical Co., Ltd. It is a thrombopoietin receptor agonist. It selectively binds and activates thrombopoietin receptors on megakaryocytes to stimulate megakaryocyte proliferation and differentiation, elevating peripheral…
Anjiayin® is the commercial brand name of Omfiloctocog alfa for Injection, developed by SCT BioPharma. It is a recombinant human coagulation factor VIII produced via gene recombination technology. It supplements deficient endogenous factor VIII in hemophilia A patients, restores normal…
Actilyse® is the commercial brand name of Alteplase for Injection, developed by Boehringer Ingelheim. It is a recombinant tissue-type plasminogen activator. It binds to fibrin in thrombi to convert plasminogen into plasmin locally, dissolving occlusive thrombi without inducing systemic extensive…